News
MNOV
1.370
+2.24%
0.030
Weekly Report: what happened at MNOV last week (0603-0607)?
Weekly Report · 2d ago
MEDICINOVA RECEIVES NOTICE OF ALLOWANCE FOR NEW PATENT COVERING MN-166 (IBUDILAST) FOR THE PREVENTION OF METASTASIS OF VARIOUS SOLID CANCER
Reuters · 06/05 10:04
Weekly Report: what happened at MNOV last week (0527-0531)?
Weekly Report · 06/03 10:33
MediciNova Presents New Data And Results Of Phase 1b/2a Clinical Trial Of MN-166 At ASCO Meeting
The combination of Temozolomide (TMZ) and MN-166 was safe and well tolerated. No unexpected adverse effects were observed in both new GBM and recurrent GBM patients. Most reported adverse events were Lymphopenia and Leukopenia.
Benzinga · 06/03 10:03
MEDICINOVA ANNOUNCES DATA FROM PHASE 1B/2A CLINICAL TRIAL OF MN-166 (IBUDILAST) IN GLIOBLASTOMA PATIENTS AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING 2024
Reuters · 06/03 10:00
MEDICINOVA INC: COMBINATION OF TEMOZOLOMIDE (TMZ) AND MN-166 WAS SAFE AND WELL TOLERATED
Reuters · 06/03 10:00
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
MediciNova, Inc. Conducted two poster presentations at the 92nd European Atherosclerosis Society (EAS) 2024 Congress held online May 26-29, 2024. The company is a biopharmaceutical company traded on the NASDAQ Global Market and the Tokyo Stock Exchange.
Barchart · 05/28 05:00
Weekly Report: what happened at MNOV last week (0520-0524)?
Weekly Report · 05/27 10:36
Weekly Report: what happened at MNOV last week (0513-0517)?
Weekly Report · 05/20 10:31
MEDICINOVA INC: PATENT IS EXPECTED TO EXPIRE NO EARLIER THAN JULY 2042
Reuters · 05/20 10:00
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
MediciNova, Inc. Received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application. The patent application covers MN-166 for the prevention of metastasis of eye cancer. The company is a biopharmaceutical company traded on the NASDAQ.
Barchart · 05/20 05:00
MEDICINOVA - GETS NOTICE OF ALLOWANCE FOR NEW PATENT COVERING MN-166 (IBUDILAST) FOR TREATING CHLORINE-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME
Reuters · 05/14 10:03
Weekly Report: what happened at MNOV last week (0506-0510)?
Weekly Report · 05/13 10:38
Medicinova, Inc. Quarterly Report for the Period Ended March 31, 2024
Press release · 05/10 21:02
MNOV Stock Earnings: MediciNova Misses EPS for Q1 2024
MediciNova reported earnings per share of -6 cents for the first quarter of 2024. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -5 cents. Medici nova also reported results for the fourth quarter of 2015.
Investorplace · 05/10 12:52
MediciNova: Q1 Earnings Snapshot
MediciNova Inc. Reported a loss of $2.8 million in its first quarter. On a per-share basis, the La Jolla, California-based company said it had a lost of 6 cents. The company reported a profit of $1.7 million in the quarter.
Barchart · 05/09 18:44
MediciNova anti-inflammatory drug gets issue notification for new patent
MediciNova anti-inflammatory drug gets issue notification for new patent. MN-166 (ibudilast) is in late-stage clinical development for the treatment of neurodegenerative diseases. The new patent is expected to expire no earlier than September 2040.
Seeking Alpha · 05/07 10:46
MEDICINOVA INC - NEW PATENT IS EXPECTED TO EXPIRE NO EARLIER THAN SEPTEMBER 2040
Reuters · 05/07 10:00
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
MediciNova, Inc. Has received a new patent for extended-release oral formulations of MN-166 (ibudilast) This new patent is expected to expire no earlier than September 2040. The allowed claims cover a formulation in the form of a tablet or capsule.
Barchart · 05/07 05:00
Weekly Report: what happened at MNOV last week (0429-0503)?
Weekly Report · 05/06 10:43
More
Webull provides a variety of real-time MNOV stock news. You can receive the latest news about Medicinova through multiple platforms. This information may help you make smarter investment decisions.
About MNOV
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.